Reliability and Validity of Thai Calgary Depression Scale of Schizophrenia (CDSS)

Depression Clinical Trial

Official title:

The Reliability and Validity of the Thai Version of Calgary Depression Scale for Schizophrenia (CDSS)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01590784
• Other study ID #: PSY-11-09-09-12
• Status: Completed
• Phase: N/A
• First received: April 27, 2012
• Last updated: July 27, 2016
• Start date: January 2012
• Est. completion date: November 2014

Study information

• Verified date: July 2016
• Source: Chiang Mai University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Thailand: Ethical Committee
• Study type: Observational

Clinical Trial Summary

Depression in patients with schizophrenia is common. Several factors was found to be associated with depression including medical illness, quality of life, positive symptoms, and typical antipsychotics. The Calgary depression scale of schizophrenia (CDSS) is commonly used for screening depression in schizophrenia,however; the Thai version of CDSS has not been validated.

This study aims to a.) test the reliability and validity of the Thai version of Calgary depression scale of schizophrenia (CDSS) and b.) identify the prevalence and factors associated with depression in patients with schizophrenia including quality of life, type of antipsychotic drugs, and severity of schizophrenia in 60 patients with schizophrenia at the Faculty of Medicine, Chiang Mai University, Thailand.

Description:

Measurements:

The Thai version of Calgary depression scale of schizophrenia (CDSS), Positive and Negative Syndrome Scale (PANSS), Hamilton Rating Scale for Depression-17 (HAM-D 17), Montgomery-Asberg Depression Rating Scale (MADRS), the Thai abbreviated version of World Health Organization quality of life (WHOQOL-BREF-THAI).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: November 2014
• Est. primary completion date: June 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• Aged 18 years or over

• Diagnosis of schizophrenia according to DSM-IV-TR

Exclusion Criteria:

• Having organic brain syndrome

• Not fluent in Thai

Study Design

Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Schizophrenia

Locations

Country	Name	City	State
Thailand	Chiang Mai University	Chiang Mai

Sponsors (1)

Lead Sponsor	Collaborator
Chiang Mai University

Country where clinical trial is conducted

Thailand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The reliability of the Thai version of the Calgary Depression Scale for Schizophrenia (CDSS) in schizophrenia patients.	The inter-rater reliability, the test-retest reliability will be analyzed.	3 months	No
Primary	The validity of the Thai version of the Calgary Depression Scale for Schizophrenia (CDSS) in schizophrenia patients.	The Positive and Negative Syndrome Scale (PANSS), Hamilton Rating Scale for Depression-17 (HAM-D 17), Montgomery-Åsberg Depression Rating Scale (MADRS) will be administered by the first rater, whereas the CDSS will be assessed by a second independent rater.	3 months	No
Secondary	The prevalence of depression in patients with schizophrenia	The point prevalence of depression in patients with schizophrenia will be presented in percentage.	3 months	No
Secondary	The association between depression in schizophrenia and quality of life.	The association between depression in schizophrenia and quality of life (WHOQOL-BREF-THAI).	3 months	No
Secondary	The association between depression in schizophrenia and type of antipsychotic drugs.	The association between depression in schizophrenia and type of antipsychotic drugs (typical vs atypical).	3 months	No
Secondary	The association between depression in schizophrenia and severity of schizophrenia.	The association between depression in schizophrenia and severity of schizophrenia (PANSS score).	3 months	No